<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="43358"><DrugName>dnaJp1</DrugName><DrugSynonyms><Name><Value>dnaJp1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>tolerogenic peptide (rheumatoid arthritis), UCSD/Androclus</Value></Name><Name><Value>heat shock protein-derived peptides (rheumatoid arthritis), Androclus</Value></Name><Name><Value>dnaJP1 (oral, rheumatoid arthritis), Pipex Pharmaceuticals</Value></Name><Name><Value>dnaJP1 (rheumatoid arthritis), Adeona Pharmaceuticals</Value></Name><Name><Value>AT-001, Androclus Therapeutics</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25451">University of California San Diego</CompanyOriginator><CompaniesSecondary><Company id="1017428">Synthetic Biologics Inc</Company><Company id="25451">University of California San Diego</Company><Company id="30549">Androclus Therapeutics</Company></CompaniesSecondary><CrossReferences><SourceEntity id="43358" type="Drug"><TargetEntity id="368128" type="siDrug">dnaJP1</TargetEntity></SourceEntity><SourceEntity id="1017428" type="Company"><TargetEntity id="4295899228" type="organizationId">Synthetic Biologics Inc</TargetEntity></SourceEntity><SourceEntity id="25451" type="Company"><TargetEntity id="4296621839" type="organizationId">University of California San Diego</TargetEntity></SourceEntity><SourceEntity id="30549" type="Company"><TargetEntity id="4297219817" type="organizationId">Androclus Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-11-13T14:34:10.000Z</LastModificationDate><ChangeDateLast>2016-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>2003-01-14T12:46:25.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017428" linkType="Company"&gt;Adeona Pharmaceuticals&lt;/ulink&gt; (formerly Pipex), presumed to be under license from   &lt;ulink linkID="25451" linkType="Company"&gt;University of California San Diego&lt;/ulink&gt; (UCSD), was developing  an oral formulation of dnaJP1(AT-001), a peptide derived from   Escherichia coli heat shock protein, for the potential treatment of rheumatoid arthritis (RA) [&lt;ulink linkID="476093" linkType="reference"&gt;476093&lt;/ulink&gt;], [&lt;ulink linkID="476110" linkType="reference"&gt;476110&lt;/ulink&gt;], [&lt;ulink linkID="953032" linkType="Reference"&gt;953032&lt;/ulink&gt;]. By April 2009, the drug was listed as being in phase II on  Adeona's website pipeline [&lt;ulink linkID="1001900" linkType="Reference"&gt;1001900&lt;/ulink&gt;]; this was still the case In November 2010 [&lt;ulink linkID="1147209" linkType="Reference"&gt;1147209&lt;/ulink&gt;]. By November 2009, Adeona was seeking to outlicense the drug [&lt;ulink linkID="1056891" linkType="Reference"&gt;1056891&lt;/ulink&gt;]. In November 2010, the company was seeking to outlicense the drug in US, Europe and Asia [&lt;ulink linkID="1147209" linkType="Reference"&gt;1147209&lt;/ulink&gt;]. However, in March 2011, development of the drug was discontinued due to strategic considerations and clinical and market potential [&lt;ulink linkID="1180493" linkType="Reference"&gt;1180493&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="30549" linkType="Company"&gt;Androclus Therapeutics&lt;/ulink&gt; was previously developing the drug [&lt;ulink linkID="816583" linkType="Reference"&gt;816583&lt;/ulink&gt;]; however, in July 2008, the company was listed as surrendered [&lt;ulink linkID="925988" linkType="Reference"&gt;925988&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By April 2009, the drug was listed as being in phase II on the Adeona's website pipeline [&lt;ulink linkID="1001900" linkType="Reference"&gt;1001900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, phase I/II trials were completed and  phase II trials were underway [&lt;ulink linkID="476093" linkType="reference"&gt;476093&lt;/ulink&gt;], [&lt;ulink linkID="539568" linkType="reference"&gt;539568&lt;/ulink&gt;]. These were completed by November 2005 [&lt;ulink linkID="623123" linkType="Reference"&gt;623123&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In September 1999, a placebo-controlled, randomized, double-blind phase II trial (&lt;ulink linkID="1944" linkType="Protocol"&gt;NCT00000435&lt;/ulink&gt;; N01 AR92241; NIAMS-042) was initiated in 160 early RA patients; 80 to be treated with 25 mg daily po for 6 months and 80 to be given placebo. The trial was completed in September 2004 [&lt;ulink linkID="476093" linkType="reference"&gt;476093&lt;/ulink&gt;], [&lt;ulink linkID="816583" linkType="Reference"&gt;816583&lt;/ulink&gt;].  In November 2005, phase II data were reported.  The double-blind, placebo-controlled, multi-center, 160-patient trial assessed a daily 25 mg oral dose of AT-001 for 6 months. Compared with a placebo, patients treated with AT-001 noticed an improvement in the signs and symptoms of RA such as swollen joints, tenderness, pain and mobility. This improvement was particularly significant at the follow-up visit on day 196, indicating the drug's sustained effect. There was also a deviation of T cell function in patients treated with AT-001 from inflammatory to regulatory. Peptide-induced T cell production of TNF-alpha between days 0 and 168 decreased significantly in the AT-001 arm, but not in the placebo arm. A  trend of increased production of IL-10 in the AT-001 arm was also seen, compared to the placebo arm [&lt;ulink linkID="632123" linkType="Reference"&gt;632123&lt;/ulink&gt;]. In March 2007, further data were presented at the SRI's 11th Inflammation and Immune Diseases Drug Discovery and Development summit in San Francisco, CA. The drug was safe and well tolerated and delivered a clear ACR response (ACR20 = 42%, ACR50 = 27%). Efficacy was augmented in patients taking hydroxychloroquine [&lt;ulink linkID="776958" linkType="Reference"&gt;776958&lt;/ulink&gt;]. In June 2007, these data were presented at the 7th FOCIS meeting in San Diego, CA [&lt;ulink linkID="810207" linkType="Reference"&gt;810207&lt;/ulink&gt;]. In October 2008, similar data were presented at 2008  American College of Rheumatology meeting in San Francisco, CA  [&lt;ulink linkID="956805" linkType="Reference"&gt;956805&lt;/ulink&gt;]. In November 2009, similar results were published [&lt;ulink linkID="1056891" linkType="Reference"&gt;1056891&lt;/ulink&gt;], [&lt;ulink linkID="1057172" linkType="Reference"&gt;1057172&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2004, results from a phase I/II trial were published. Patients with early RA were treated with dnaJp1 orally for 6 months. The peptide caused no side effects and induced a change from pro-inflammatory to regulatory T-cell function. Peptide-induced T-cell production of IL-4 and IL-10 increased as a result of the treatment, while peptide-induced T-cell proliferation and production of IL-2, interferon-gamma and TNF-alpha decreased. Responses to unrelated antigens did not change, confirming the antigen-specific nature of the treatment [&lt;ulink linkID="538679" linkType="reference"&gt;538679&lt;/ulink&gt;], [&lt;ulink linkID="538670" linkType="reference"&gt;538670&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By 2000, a phase I trial had been completed in 13 RA patients. No toxicity or immunogenicity was observed. 85% showed an ACR 20 response, 46% showed an ACR 50 response and 31% showed an ACR 70 response. Clinical responses correlated with immunological responses of their PBMC in vitro in seven of eight patients analyzed [&lt;ulink linkID="476093" linkType="reference"&gt;476093&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2005, data were published describing the in vitro immunoscreening of a series of heat shock protein 60-derived peptides in patients with  JIA. Researchers identified eight potential hsp60 T-cell epitopes, and analyzed the T-cell response these induced in the peripheral-blood mononuclear cells of 57 JIA patients, 27 healthy controls and 20 disease controls. Five of the eight peptides yielded a proliferative T-cell response in the JIA patients but not in the controls, suggesting that the peptides could represent an immunomodulatory treatment for  JIA. [&lt;ulink linkID="612534" linkType="Reference"&gt;612534&lt;/ulink&gt;], [&lt;ulink linkID="612522" linkType="Reference"&gt;612522&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2008, Pipex Pharmaceuticals acquired a phase ll oral once-daily therapeutic for the treatment of rheumatoid arthritis, dnaJP1 (AT-001), presumed to be from the University of California San Diego [&lt;ulink linkID="936326" linkType="Reference"&gt;936326&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2008, the program had been supported by the National Institutes of Health (NIH) with a $5 million grant [&lt;ulink linkID="936326" linkType="Reference"&gt;936326&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2004, Androclus had licensed exclusive rights to University of California San Diego's immunomodulator therapies including AT-001 [&lt;ulink linkID="538670" linkType="Reference"&gt;538670&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2003, the company claimed that it was strategically partnered with a large biotechnology company for the AT-001 project [&lt;ulink linkID="476110" linkType="Reference"&gt;476110&lt;/ulink&gt;]. By August 2005, this partnership was ongoing but the partner had not  been announced [&lt;ulink linkID="619664" linkType="Reference"&gt;619664&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The dnaJp1 peptide contains the QKRAAYDQYGHAAFE amino acid sequence, found in the HLA gene which is associated with susceptibility to RA [&lt;ulink linkID="476115" linkType="reference"&gt;476115&lt;/ulink&gt;], [&lt;ulink linkID="983539" linkType="Reference"&gt;983539&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017428">Synthetic Biologics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-03-31T00:00:00.000Z</StatusDate><Source id="1180493" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30549">Androclus Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-17T00:00:00.000Z</StatusDate><Source id="925988" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-05-14T00:00:00.000Z</StatusDate><Source id="538670" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-09-30T00:00:00.000Z</StatusDate><Source id="816583" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30549">Androclus Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-09-30T00:00:00.000Z</StatusDate><Source id="816583" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1992-12-31T00:00:00.000Z</StatusDate><Source id="476115" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017428">Synthetic Biologics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-19T00:00:00.000Z</StatusDate><Source id="936326" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1017428">Synthetic Biologics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20547">University of California</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="30549">Androclus Therapeutics</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H](C(=O)N[C@@H](Cc1ccc(cc1)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)NCC(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N</Smiles></StructureSmiles><Deals><Deal id="108166" title="Androclus Therapeutics to develop UCSD's immunomodulators, including AT-001"></Deal><Deal id="114855" title="Pipex Pharmaceuticals to develop UCSD's dnaJP1"></Deal><Deal id="124895" title="NIH to award funding to Pipex for development of dnaJp1 program"></Deal></Deals><PatentFamilies><PatentFamily id="206666" number="WO-00212286" title="Stress proteins and peptides and methods of use thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synthetic Biologics Inc" id="1017428"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Androclus Therapeutics" id="30549"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>